885518-53-6 Usage
General Description
4-Bromo-6-amino (1H)indazole is a chemical compound with the molecular formula C7H6BrN3. It is a heterocyclic aromatic organic compound that contains a bromine atom and an amino group on the 6th and 4th position of the indazole ring, respectively. 4-BROMO-6-AMINO (1H)INDAZOLE is commonly used as a building block in the synthesis of pharmaceuticals, agrochemicals, and organic compounds. It is also known for its potential application in medicinal chemistry, particularly in the development of novel drugs targeting various biological pathways. 4-Bromo-6-amino (1H)indazole has been studied for its bioactivity and has shown potential as an anticancer agent and an inhibitor of certain enzymes and proteins. It is an important chemical intermediate with versatile synthetic applications and potential pharmacological properties.
Check Digit Verification of cas no
The CAS Registry Mumber 885518-53-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,5,5,1 and 8 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 885518-53:
(8*8)+(7*8)+(6*5)+(5*5)+(4*1)+(3*8)+(2*5)+(1*3)=216
216 % 10 = 6
So 885518-53-6 is a valid CAS Registry Number.
885518-53-6Relevant articles and documents
KRAS G12C Inhibitor and application thereof
-
Paragraph 0232; 0321-0324, (2021/03/31)
The invention discloses a novel KRAS G12C inhibitor, wherein the compound as shown in a formula I, and an isomer or pharmaceutically acceptable salt thereof have the following structure. The compoundas shown in the formula I and the composition thereof di
Synthesis of substituted 4-(1H-indol-6-yl)-1H-indazoles as potential PDK1 inhibitors
Brzozowski, Martin,O'Brien, Nathan J.,Wilson, David J.D.,Abbott, Belinda M.
, p. 318 - 326 (2014/01/06)
The development of a preparative route to a series of novel 4-(1H-indol-6-yl)-1H-indazole compounds as potential PDK1 inhibitors is described. The synthetic strategy centres on the late-stage Suzuki cross-coupling of N-unprotected indazole and indole frag
